Documentation a pain management group will want to see
Multi-physician pain management and physical medicine groups often route a new vendor through a compliance review before any prescriber places an order. That review typically covers the lot release record, the donor eligibility summary, and confirmation that each lot underwent third-party sterility testing during a quarantine hold.
We provide this documentation set to every verified Detroit account, organized by lot, so a group practice can match paperwork to the specific units a given provider ordered.
Detroit
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
92- Pain Medicine
- 44
- Physical Medicine & Rehabilitation
- 48
NPI verification before the first shipment
Accounts are limited to licensed physicians and clinics ordering under physician supervision. We verify the NPI tied to each account before activation, and a practice manager can start the application while the account itself stays under the physician of record.
Verified accounts can request a peer-to-peer call covering documentation, lot numbering, and traceability. These calls are not a substitute for the practice's own clinical judgment or regulatory review.
Shipping into the Midwest region
Cryopreserved Wharton's jelly and exosome formats travel overnight on dry ice in validated containers and need to move into -80 degree Celsius storage promptly on arrival. A Detroit practice should confirm freezer space ahead of the delivery date rather than after the shipment lands. Lyophilized formats are shelf-stable and ship without that cold-chain step.
Because each lot carries a unique identifier, we recommend recording it at the patient-record level, which most multi-provider pain practices already do for other biologic inventory.
Confirm classification questions with your medical board and counsel
There are no FDA-approved exosome products, and these formulations are generally regulated as biologic drugs rather than under the 361 HCT/P pathway used for many Wharton's jelly products. Whether a given Wharton's jelly product and its intended use in your practice satisfies the minimal-manipulation and homologous-use criteria is a question for your own counsel, not a determination we make for you.
We recommend Detroit practices check their marketing materials and intended-use language against guidance from the Michigan medical board and their own healthcare attorney, particularly given FDA warning letters issued to distributors in 2026 over website and social media claims.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Do you work with pain management groups in Detroit?+
Yes. We open NPI-verified accounts for licensed pain management and physical medicine physicians and groups in Detroit and provide the same documentation set to every verified account.
Can a group account cover more than one prescriber?+
Yes. The account is held under the supervising physician's NPI, and a practice manager can coordinate ordering across multiple prescribers within that account.
How are Wharton's jelly and exosome products regulated differently?+
Wharton's jelly products are offered under the supplier's HCT/P framework, while exosome products have no FDA approval and are generally regulated as biologic drugs. Your counsel should confirm how a specific use is classified.